{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["33(6)"],"submitter":["Dahdah L"],"funding":["Danone Nutricia Research"],"pubmed_abstract":["<h4>Background</h4>Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA).<h4>Objectives</h4>Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey-protein formula (eHWF) in CMA children were assessed.<h4>Methods</h4>In this prospective, randomized, international, multi-center study (Trial NL3889), 34 children with confirmed CMA (74% IgE-mediated) underwent a double-blind, placebo-controlled food challenge (DBPCFC) with an eHWF developed with non-porcine enzymes, supplemented with prebiotic short-chain galacto- and long-chain fructo-oligosaccharides (0.8 g/L, ratio 9:1), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participa"],"journal":["Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology"],"pagination":["e13814"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9542408"],"repository":["biostudies-literature"],"pubmed_title":["Hypoallergenicity assessment of an extensively hydrolyzed whey-protein formula in cow's milk allergic infants."],"pmcid":["PMC9542408"],"pubmed_authors":["Rijnierse A","Brand PLP","Fiocchi A","Knipping K","de Vries E","Roelofs M","Dahdah L","Garssen J"],"additional_accession":[]},"is_claimable":false,"name":"Hypoallergenicity assessment of an extensively hydrolyzed whey-protein formula in cow's milk allergic infants.","description":"<h4>Background</h4>Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA).<h4>Objectives</h4>Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey-protein formula (eHWF) in CMA children were assessed.<h4>Methods</h4>In this prospective, randomized, international, multi-center study (Trial NL3889), 34 children with confirmed CMA (74% IgE-mediated) underwent a double-blind, placebo-controlled food challenge (DBPCFC) with an eHWF developed with non-porcine enzymes, supplemented with prebiotic short-chain galacto- and long-chain fructo-oligosaccharides (0.8 g/L, ratio 9:1), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-22T12:07:59.276Z","creation":"2025-04-06T00:12:24.264Z"},"accession":"S-EPMC9542408","cross_references":{"pubmed":["35754130"],"doi":["10.1111/pai.13814"]}}